Dysregulation of EGFR signaling, either through receptor overexpression, constitute activation of the receptor due to gene mutation or ligand stimulation, is frequently observed in NSCLC and is associated with poor progression and resistance to therapy [12, 13]. Here, EGFR is linked to non-small cell lung carcinoma.